NSE - Delayed Quote INR

AstraZeneca Pharma India Limited (ASTRAZEN.NS)

Compare
6,564.20 +62.55 (+0.96%)
At close: November 29 at 3:29 PM GMT+5:30
Advanced Chart
Loading Chart for ASTRAZEN.NS
DELL
  • Previous Close 6,501.65
  • Open 6,547.00
  • Bid --
  • Ask --
  • Day's Range 6,462.80 - 6,590.00
  • 52 Week Range 4,600.70 - 8,139.00
  • Volume 9,194
  • Avg. Volume 97,556
  • Market Cap (intraday) 164.105B
  • Beta (5Y Monthly) 0.29
  • PE Ratio (TTM) 200.01
  • EPS (TTM) 32.82
  • Earnings Date Feb 6, 2025 - Feb 10, 2025
  • Forward Dividend & Yield 24.00 (0.32%)
  • Ex-Dividend Date Jul 5, 2024
  • 1y Target Est --

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

www.astrazeneca.in

940

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

More about AstraZeneca Pharma India Limited

Recent News: ASTRAZEN.NS

View More
View More

Performance Overview: ASTRAZEN.NS

Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ASTRAZEN.NS
19.18%
S&P BSE SENSEX
10.47%

1-Year Return

ASTRAZEN.NS
38.82%
S&P BSE SENSEX
20.60%

3-Year Return

ASTRAZEN.NS
108.51%
S&P BSE SENSEX
39.74%

5-Year Return

ASTRAZEN.NS
148.51%
S&P BSE SENSEX
94.02%

Compare To: ASTRAZEN.NS

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

ASTRAZEN.NS
AstraZeneca Pharma India Limited
6,564.20
+0.96%
Mkt Cap INR 164.105B
Industry Drug Manufacturers—Specialty & Generic
KILITCH.NS
Kilitch Drugs (India) Limited
315.60
+1.59%
Mkt Cap INR 5.115B
Industry Drug Manufacturers—Specialty & Generic
MEDICAMEQ.NS
Medicamen Biotech Limited
443.45
+0.59%
Mkt Cap INR 5.64B
Industry Drug Manufacturers—Specialty & Generic
HESTERBIO.NS
Hester Biosciences Limited
2,596.80
-0.12%
Mkt Cap INR 22.214B
Industry Drug Manufacturers—Specialty & Generic
ALBERTDAVD.NS
Albert David Limited
1,292.20
+1.60%
Mkt Cap INR 7.416B
Industry Drug Manufacturers—Specialty & Generic
INNOVACAP.NS
Innova Captab Limited
1,021.90
+1.68%
Mkt Cap INR 58.478B
Industry Drug Manufacturers—Specialty & Generic
THEMISMED.NS
Themis Medicare Limited
292.50
+2.88%
Mkt Cap INR 26.922B
Industry Drug Manufacturers—Specialty & Generic
ERIS.NS
Eris Lifesciences Limited
1,440.15
+1.55%
Mkt Cap INR 196.053B
Industry Drug Manufacturers—Specialty & Generic
NEULANDLAB.BO
Neuland Laboratories Limited
16,691.40
+0.59%
Mkt Cap INR 214.149B
Industry Drug Manufacturers—Specialty & Generic
AARTIPHARM.NS
Aarti Pharmalabs Limited
633.90
+1.52%
Mkt Cap INR 57.461B
Industry Drug Manufacturers—Specialty & Generic
RPGLIFE.NS
RPG Life Sciences Limited
2,217.45
+3.79%
Mkt Cap INR 36.674B
Industry Drug Manufacturers—Specialty & Generic

Statistics: ASTRAZEN.NS

View More

Valuation Measures

Annual
As of 11/29/2024

  • Market Cap

    164.05B

  • Enterprise Value

    159.14B

  • Trailing P/E

    200.31

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.05

  • Price/Book (mrq)

    24.16

  • Enterprise Value/Revenue

    10.72

  • Enterprise Value/EBITDA

    120.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.91%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    13.88B

  • Net Income Avi to Common (ttm)

    958.6M

  • Diluted EPS (ttm)

    32.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.06B

  • Total Debt/Equity (mrq)

    0.64%

  • Levered Free Cash Flow (ttm)

    --

View More

Research Analysis: ASTRAZEN.NS

View More
View More

Company Insights: ASTRAZEN.NS

Research Reports: ASTRAZEN.NS

View More
View More

People Also Watch

SANOFI.NS Sanofi India Limited
6,390.50
+3.22%
 
PFIZER.NS Pfizer Limited
5,313.25
+0.14%
 
ABBOTINDIA.NS Abbott India Limited
27,723.40
+1.26%
 
APLLTD.NS Alembic Pharmaceuticals Limited
1,092.20
+1.04%
 
ALKEM.NS Alkem Laboratories Limited
5,642.45
+3.40%
 
AJANTPHARM.NS Ajanta Pharma Limited
3,022.55
+3.15%
 
JBCHEPHARM.NS J. B. Chemicals & Pharmaceuticals Limited
1,735.30
+0.51%
 
ATUL.NS Atul Ltd
7,295.80
+0.99%
 
AKZOINDIA.NS Akzo Nobel India Limited
3,707.20
-0.75%
 
IPCALAB.NS Ipca Laboratories Limited
1,542.55
+1.95%
 
BASF.NS BASF India Limited
6,016.75
+1.41%
 
3MINDIA.NS 3M India Limited
32,245.30
+0.63%
 
PGHL.NS Procter & Gamble Health Limited
5,177.05
+0.16%
 
ERIS.NS Eris Lifesciences Limited
1,440.15
+1.55%
 
BLUEDART.NS Blue Dart Express Limited
7,505.55
+0.11%
 
BAYERCROP.NS Bayer CropScience Limited
5,692.30
+0.73%